PHK
IBRX icon

Point72 Hong Kong’s ImmunityBio IBRX Stock Holding History

Point72 Hong Kong’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,782
Closed -$55K – 2142
2022
Q2 		$55K Buy
14,782
+8,633
+140% +$34.7K ﹤0.01% 1353
2022
Q1 		$34K Buy
6,149
+5,874
+2,136% +$36K ﹤0.01% 1430
2021
Q4 		$2K Buy
+275
New +$2.07K ﹤0.01% 1776
2021
Q3 		– Sell
-310
Closed -$4K – 2198
2021
Q2 		$4K Buy
+310
New +$5.12K ﹤0.01% 1806
2020
Q4 		– Sell
-6,987
Closed -$48K – 1867
2020
Q3 		$48K Buy
+6,987
New +$69.7K 0.01% 682

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Hong Kong's IBRX Position: Q3 2022 in Review

Point72 Hong Kong sold out of ImmunityBio (IBRX) in Q3 2022, closing a stake of 14,782 shares — an estimated $55K sold.

Point72 Hong Kong first reported a position in IBRX in Q3 2020 and held it in 5 quarters. The position peaked at $55K in Q2 2022. 126 funds tracked by Wall St. Rank hold IBRX as of Q3 2022.

  • Point72 Hong Kong reported no remaining ImmunityBio position as of Q3 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 14,782 ImmunityBio shares in Q3 2022, an estimated $55K.
  • Point72 Hong Kong first reported a position in ImmunityBio in Q3 2020 and held it in 5 quarters.
  • Point72 Hong Kong's ImmunityBio position peaked at $55K in Q2 2022.
  • 126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.